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The current photosensitizers (PSs) for photodynamic therapy (PDT) lack selectivity for cancer cells. To tackle
this drawback, in view of selective cancer delivery, we envisioned conjugating two ruthenium polypyridyl
complexes to vitamin B12 (Cobalamin, Cbl) to take advantage of the solubility and active uptake of the latter.
Ultimately, our results showed that the transcobalamin pathway is unlikely involved for the delivery of these
ruthenium-based PDT PSs, emphasizing the difficulty in successfully delivering metal complexes to cancer cells.
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Introduction
Photodynamic therapy (PDT) is an approved medical
technique that relies on the use of a photosensitizer
(PS) to ultimately generate reactive oxygen species
(ROS) or radicals that can trigger cell death.[1] The
interest of this method is its spatio-temporal control.
The PS is activated only when and where the physician
applies light. In brief, upon irradiation at a specific,
defined wavelength, an electron of the ground state of
the PS reaches a singlet excited state (1PS*), which
then reaches a triplet state (3PS*) through an inter-
system crossing (ISC) event.[2] The PDT process can
then rely on two types of mechanism: 1) in Type I, an
electron or proton transfer from the species 3PS* to a
biological substrate that generates radicals which can
further react with molecular oxygen and form super-
oxides, hydroxyl radicals, or peroxides, or 2) in Type II,
an energy transfer from 3PS* to molecular oxygen in
its ground triplet state (3O2) to generate the highly
toxic singlet oxygen (1O2).
[3]
The currently used PSs in the clinic are mainly
based on cyclic tetrapyrrolic scaffolds (chlorins, phtha-
locyanines, and porphyrins[4]). Their main drawbacks
are a lack of selectivity towards cancers cells, low
water solubility, an important photobleaching and,
sometimes, serious problems of photosensitivity for
the treated patients.[5] Ru(II) polypyridyl complexes
were found to be an interesting alternative to the
current PDT PSs. Although the use of such compounds
as PDT PS against cancer is relatively recent, the results
are spectacular with one of such compounds, TLD-
1433, having recently completed phase I clinical trial
against bladder cancer.[2,6–10] We note that to reach
the therapeutic window for PDT treatment (ca. 600 to
800 nm), some Ru(II) polypyridyl complexes were
found to be good PSs for two-photon PDT,[11–13]
further illustrating the versatility of ruthenium in
medicinal chemistry. To further improve the properties
of the Ru(II)-based PDT PSs, it is also possible to
conjugate them with targeting moieties, or to asso-
ciate them in non-covalent manner with serum or
1 These authors have contributed equally to the work.
Supporting information for this article is available on the
WWW under https://doi.org/10.1002/hlca.201900104
1
htt
p:/
/do
c.r
ero
.ch
Published in "Helvetica Chimica Acta 102(7): , 2019" which should be cited to refer to this work.
membrane proteins.[14–16] Another possible strategy
envisioned by our group and by others is the
encapsulation of the Ru(II)-based PDT agents in
polymers or their functionalization to
nanoparticles.[17–19]
Vitamin B12 is a vital nutrient that is characterized by
a low bioavailability. Because it is playing an essential
role in cell proliferation, it is crucial for fast growing
cells.[20] This interesting characteristic was already used in
several studies[21] in which cobalamin was employed as a
targeting moiety for metal complexes to direct them
towards fast dividing malignant cells.[22–24] With this in
mind, in this work, we aimed at developing a system for
improving the solubility and uptake of Ru(II)-based PSs
into cancer cells. Our hope was that the resulting
conjugates would have a good water solubility and an
active cellular uptake.[25,26] Indeed, in the systemic
circulation, Cbl is brought to the cells by a carrier protein
named transcobalamin and ultimately taken up follow-
ing a receptor-mediated endocytosis.[13,27] Therefore, two
trisbipyridyl ruthenium(II) complexes were conjugated to
vitamin B12 (Cobalamin, Cbl). After characterization of the
new conjugate B12-2, both molecules were tested in vitro
to evaluate their efficiency in PDT as well as their cellular
uptake. This data were compared with the Ru(II)
complexes themselves.
Results and Discussion
Compounds Design and Chemistry
As a cofactor, inside cells, cob(III)alamine is ultimately
reduced to cob(I)alamine. During this process, the ?-
upper ligand of cobalamin becomes labile.[28] This
feature has been explored in the past to attach drugs/
drug candidates at this position.[29] However, chemical
modifications at the ?-position were for a long time
restrained by synthetic constraints as well as the
instability of the resulting derivatives.[30] Recent ad-
vances in organometallic chemistry of cobalamin have
allowed to generate stable derivatives and to rethink
this prodrug approach.[31,32] As a prerequisite, the
chosen compounds should bear an accessible alkyne
group which can be directly attached to the cobalt
center of Cbl following a copper-mediated reaction as
described by Gryko and coworkers.[33] Two bispyridyl
ruthenium(II) complexes were chosen and adapted to
the need of this coupling reaction: a cytotoxic
compound, which was previously reported to accumu-
late at the plasma membranes of ovarian carcinoma
cell line A2780, [Ru(NNbpy)3]
2+ (where NNbpy=
diethylamino-2,2’-bipyridine) and the standard [Ru
(bpy)3]
2+ (bpy: 2,2’-bipyridine).[34] These two com-
pounds were synthesized asymmetrically in order to
substitute one of the original bipyridyl ligands by a 4-
ethynyl-2,2’-bipyridine ligand (CCbpy), as previously
reported to give [Ru(NNbpy)2(CCbpy)]2+ (1) and [Ru
(bpy)2(CCbpy)]2+ (2) as shown in Figure 1.[35,36]
The complexes 1 and 2 were then coupled to
cobalamin in good yield by adapting Gryko’s
procedure[31] to give two B12 derivatives: B12-1 and B12-
2 (see Figure 1). The compounds were unambiguously
characterized by 1H-NMR and HR-ESI-MS and their
purity verified by HPLC (see Supporting Information).
Very importantly, all compounds were found stable in
water for at least seven days as well as light stable
over the same time period.
Photophysical Properties
With both compounds in hand, we investigated their
photophysical properties to evaluate their potential as
PDT PSs (Tables 1 and 2). As a first experiment, the
absorption of the compounds was measured in MeOH
and compared with their B12-conjugates (Figure 1, right
side). Since the necessary 3MLCT band centered at
450 nm did not significantly change, we assume that
the photophysical properties of the conjugate should
Figure 1. Ruthenium complexes and B12 conjugates used in this
study.
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not be influenced through the conjugation. As a
second experiment, the emission of the compounds
was investigated upon excitation at 450 nm in MeCN.
Compound 2 has an emission maximum at 635 nm
and a luminescence quantum yield of 0.02. These
values are in the same range as other Ru(II) polypyr-
idine complexes.[37,38] However, the emission of 1 was
barely measurable with the apparatus in our labora-
tory. As a third experiment, the luminescence lifetimes
were determined and their influence on the presence
of air investigated. Due to the very low emission of
complex 1, its lifetime was not detected. This contrasts
with the lifetime of compound 2 which was found to
be in the same range than other Ru(II) polypyridyl
complexes.[37,38] Importantly, the excited state lifetime
changed drastically upon the presence of oxygen
indicating that 3O2 is able to interact with the excited
state of 2.
After showing that our compounds are able to
interact with oxygen, we investigated quantitatively
the production of singlet oxygen (1O2) upon light
exposure. This is a crucial factor for a PS since 1O2 is
known to be the major active species for most applied
PSs in the clinics. For this purpose, two different
methods have been used: 1) direct by measurement of
the phosphorescence of 1O2, 2) indirect by measure-
ment of the change in absorbance of a reporter
molecule.[39] Worthy of note, only singlet oxygen
quantum yields over 20% can be detected via the
direct method with our apparatus. The results shown
in Table 2 demonstrate that compounds 1 and 2 are
producing 1O2 only poorly. This could be explained by
the weak population of the excited state indicated by
the poor luminescence properties of the complexes
(Table 1) which is a necessary requirement for the
production of 1O2.
Evaluation of PDT Activity
Dark and light cytotoxicity of the complexes was
investigated in the cervical cancer cell line (HeLa) and
non-cancerous retina pigmented epithelium (RPE-1)
cell lines (Table 3). It was expected that the B12
derivatives would be more toxic to both cell lines due
to the presence of B12 that should increase their
uptake. Surprisingly, compound 2 and its derivative
B12-2 showed no cytotoxicity either in the dark or
upon light irradiation. On the contrary, complex 1 was
found to be cytotoxic in the dark (IC50: 9.331.43 ?M
and 6.080.085 ?M in HeLa and RPE-1 cell lines,
respectively). Irradiation at 480 nm (10 min;
3.21 Jcm2) did not significantly increase its toxicity.
Photoindex (PI) values (IC50 dark/IC50 light) of 1.3 and
1.1 for HeLa and RPE-1 cell lines, respectively, were
determined. To our surprise, the B12-1 complex was
found to be not toxic in the dark. Light irradiation of
cells treated with B12-1 did not cause toxicity in the
RPE-1 or in the HeLa cell lines (see results in Table 1).
Overall, these studies did not show any correlation
between the presence of vitamin B12 and (photo-)
toxicity, clearly emphasizing that the coupling of Cbl
was not helping in the delivery of our Ru(II) complexes.
An obvious reason could be the bulkiness of the Ru(II)
complexes. In a more general context, these disap-
Table 1. Photophysical properties of 1 and 2 in MeCN.
?em=emission maximum, ?em= luminescence quantum yield,
?= luminescence lifetime, n.d.=not detectable.
Compound ?em [nm] ?em ? [ns]
air degassed
1 695 >0.001 n.d. n.d.
2 635 0.021 226 679
Table 2. Singlet oxygen quantum yields in MeCN and aqueous
solution determined at 450 nm. Average of three independent
measurements, n.d.=not detectable.
Compound direct
450 nm
MeCN
direct
450 nm
D2O
indirect
450 nm
MeCN
indirect
450 nm
PBS
1 n.d. n.d. 8% 3%
2 n.d. n.d. 19% 7%
Table 3. IC50 values of complexes incubated with RPE-1 or HeLa cell line in the dark and upon light irradiation (in?M).
Compound Cell line
RPE-1 HeLa
Dark Light PI value Dark Light PI value
1 6.080.085 5.430.060 1.1 9.331.43 7.140.13 1.3
B12-1 >100 >100 – >100 >100 –
2 >100 >100 – >100 >100 –
B12-2 >50 >50 – >50 >50 –
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pointing results highlight the difficulty in specifically
delivering metal complexes to cancer cells.
Ru(II) polypyridyl complexes are usually known to
be highly luminescent.[40] We have therefore used this
characteristic to further investigate the cellular biodis-
tribution of the complexes in cells, and confocal
microscopy studies were performed. Disappointingly,
these two Ru(II) complexes as well as their B12
derivatives showed very weak or no luminescent signal
in treated HeLa cells (see Figure S13). For this reason,
cellular localization could not be precisely determined,
although localization in the cytoplasm could be faintly
observed.
Conclusions
In this article, we have presented the evaluation of
trisbipyridyl Ru(II) complexes 1 and 2 conjugated with
vitamin B12 as potential photosensitizers for PDT. The
conjugation with cobalamin increased the water
solubility of the compounds, especially for complex 1
which was found to be extremely poorly soluble in
this solvent. Unfortunately, our ruthenium-containing
conjugates were found to not have any significant
phototoxic activity to the cell lines studied in this
work. In addition, we could not precisely determine
the cellular localization of the complexes by confocal
microscopy due to either the lack of luminescence of
the Ru(II) complexes or due to the very poor uptake of
the compounds. Overall, this study suggests that the
transcobalamin pathway is unlikely involved for the
uptake of our Ru(II) conjugates. It would be interesting
to assess if this is true with other Ru(II) polypyridyl
complexes.
Experimental Section
General Experimental Details
All chemicals were purchased from Sigma-Aldrich (St.
Louis, MO) and used without further purification. The
ligand 4-ethynyl-2,2’-bipyridine was synthesized ac-
cording to a published procedure as well as the Ru
complexes 1 and 2 and the B12 derivative B12-1.
[15,16]
HPLC Analyses were performed on a Merck-Hitachi
L7000. The analytical separations were conducted on a
Macherey-Nagel Nucleodur PolarTec column (5 ?m
particle size, 110 Å pore size, 250×3mm). The prepara-
tive separations were conducted on a Macherey-Nagel
Nucleodur C18 HTec column (5 ?m particle size, 110 Å
pore size, 250×21 mm). HPLC solvents were water (A)
and methanol (B). The compounds were separated
using the following gradient: 0–5 min (75% solvent A),
5–35 (75% solvent A!0% solvent A), 35–45 min
(100% solvent B). The flow rate was set to 0.5 mlmin1
for analytical separations and 5 mlmin1 for the
preparative ones. The eluting bands were detected at
320 nm. High resolution ESI-MS was performed on a
Bruker FTMS 4.7-T Apex II (positive mode) and the UV/
Vis spectra recorded on a Jasco V-730. nmR Analyses
were recorded on a Bruker Avance III 500 MHz. The
corresponding 1H and 13C chemical shifts are reported
relative to residual solvent protons and carbons.
Synthesis and Characterization of the Derivative B12-2
The following procedure was adapted from the
literature to achieve the synthesis of the B12
derivatives.[13] A mixture of cyanocobalamin (20 mg,
0.013 mmol, 1 equiv.), CuOAc (2.3 mg, 0.0013 mmol,
0.1 equiv.) and the alkyne 2 (0.07 mmol, 5 equiv.) in
DMA (3.5 ml) was stirred until dissolution. DBU
(0.01 ml, 0.7 mmol, 5 equiv.) was added and the
solution was allowed to react at room temperature for
4 h. The respective crudes were precipitated by
dropwise addition to a stirred solution of diethyl
ether/CH2Cl2 (50 ml, 1 : 1). The residue was dissolved in
a mixture of MeOH and water (2 ml, 1 :1), filtered
again, and purified by preparative HPLC. The eluting
band containing the desired product was isolated and
lyophilized.
Data for B12-2: Isolated as a brownish powder, yield
19.8 mg (70%). HPLC: tR=14.5 min. UV/Vis (MeOH): 330,
363, 460, 519, 552. 1H-NMR (500 MHz, (D4)methanol):
8.53 (t, J=9.5, 4 H); 8.25 (t, J=9.37, 1 H); 8.09–7.99 (m, 5
H); 7.85–7.69 (m, 6 H); 7.54 (dd, J=6.0, 2.37, 1 H); 7.40–
7.32 (m, 5 H); 7.29 (s, 1 H); 7.14 (s, 1 H); 6.82–6.76 (m, 1
H); 6.50 (s, 1 H); 6.37 (d, J=3.2, 1 H); 6.05 (d, J=3.8, 1 H);
4.38–4.23 (m, 2 H); 4.13–4.07 (m, 1 H); 3.95 (dd, J=13.0,
2.45, 1 H); 3.78 (dd, J=13.0, 4.0, 2 H); 3.62 (d, J=14.3, 1
H); 3.43–3.35 (m, 2 H); 3.32–3.25 (m, 2 H); 2.99 (dd, J=
9.0, 5.3, 2 H); 2.79–2.32 (m, 16 H); 2.27 (s, 6 H); 2.14 (t, J=
12.0, 1 H); 2.09–1.93 (m, 7 H); 1.89–1.77 (m, 5 H); 1.45 (d,
J=4.2, 3 H); 1.40 (d, J=3.4, 3 H); 1.34 (s, 3 H); 1.27 (d, J=
6.3, 3 H); 1.18 (s, 1 H); 1.15 (s, 3 H); 1.13–1.02 (m, 2 H);
0.52 (s, 3 H). HR-ESI-MS (pos.): 960.8315 (M2+,
C94H111Co11 N19O14P1Ru1
2+; calc. 960.8342).
Spectroscopic Measurements
The emission was measured by irradiation of the
sample in fluorescence quartz cuvettes (width 1 cm)
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using a NT342B Nd-YAG pumped optical parametric
oscillator (Ekspla) at 450 nm. Luminescence was fo-
cused and collected at right angle to the excitation
pathway and directed to a Princeton Instruments Acton
SP-2300i monochromator. As a detector a XPI-Max 4
CCD camera (Princeton Instruments) has been used.
Luminescence Quantum Yield Measurements
For the determination of the luminescence quantum
yield, the samples were prepared in a MeCN solution
with an absorbance of 0.2 at 450 nm. This solution was
irradiated in fluorescence quartz cuvettes (width 1 cm)
using a NT342B Nd-YAG pumped optical parametric
oscillator (Ekspla) at 450 nm. The emission signal was
focused and collected at right angle to the excitation
pathway and directed to a Princeton Instruments Acton
SP-2300i monochromator. As a detector a XPI-Max 4
CCD camera (Princeton Instruments) has been used.
The luminescence quantum yields were determined
by comparison with the reference [Ru(bipy)3]Cl2 in
MeCN (?em=0.059)[41] applying the following formula:
Fem,S ¼ Fem,R*ðFR=FSÞ*ðIS=IRÞ*ðnS=nRÞ2
F ¼ 110A
?em= luminescence quantum yield, F= fraction of
light absorbed, I= integrated emission intensities, n=
refractive index, A=absorbance of the sample at
irradiation wavelength, R= reference, S= sample.
Lifetime Measurements
For the determination of the lifetimes, the samples
were prepared in an air saturated and in a degassed
MeCN solution with an absorbance of 0.2 at 450 nm.
This solution was irradiated in fluorescence quartz
cuvettes (width 1 cm) using a NT342B Nd-YAG pumped
optical parametric oscillator (Ekspla) at 450 nm. The
emission signal was focused and collected at right
angle to the excitation pathway and directed to a
Princeton Instruments Acton SP-2300i monochromator.
As a detector a R928 photomultiplier tube (Hamamat-
su) has been used.
Singlet Oxygen Measurements
Direct Evaluation
The samples were prepared in an air saturated MeCN
or D2O solution with an absorbance of 0.2 at 450 nm.
This solution was irradiated in fluorescence quartz
cuvettes (width 1 cm) using a mounted M450LP1 LED
(Thorlabs) whose irradiation, centered at 450 nm, has
been focused with aspheric condenser lenses. The
intensity of the irradiation has been varied using a T-
Cube LED Driver (Thorlabs) and measured with an
optical power and energy meter. The emission signal
was focused and collected at right angle to the
excitation pathway and directed to a Princeton Instru-
ments Acton SP-2300i monochromator. A longpass
glass filter was placed in front of the monochromator
entrance slit to cut off light at wavelengths shorter
than 850 nm. As a detector an EO-817L IR-sensitive
liquid nitrogen cooled germanium diode detector
(North Coast Scientific Corp.) has been used. The singlet
oxygen luminescence at 1270 nm was measured by
recording spectra from 1100 to 1400 nm. For the data
analysis, the singlet oxygen luminescence peaks at
different irradiation intensities were integrated. The
resulting areas were plotted against the percentage of
the irradiation intensity and the slope of the linear
regression calculated. The absorbance of the sample
was corrected with an absorbance correction factor. As
reference for the measurement in an MeCN solution
phenalenone (?phenaleone=95%)[42] and for the meas-
urement in a D2O solution [Ru(bipy)3]Cl2 (?Ru(bipy)3Cl2=
22%)[43] was used and the singlet oxygen quantum
yields were calculated using the following formula:
FS ¼ FR*ðSS=SRÞ*ðIR=ISÞ
I ¼ I0*ð110AÞ
?= singlet oxygen quantum yield, S= slope of the
linear regression of the plot of the areas of the singlet
oxygen luminescence peaks against the irradiation
intensity, I=absorbance correction factor, I0= light
intensity of the irradiation source, A=absorbance of
the sample at irradiation wavelength, R= reference,
S= sample.
Indirect Evaluation
For the measurement in MeCN: The samples were
prepared in an air-saturated MeCN solution containing
the complex with an absorbance of 0.2 at the
irradiation wavelength, N,N-dimethyl-4-nitrosoaniline
(RNO, 24 ?M) and imidazole (12 mM). For the measure-
ment in PBS buffer: The samples were prepared in an
air-saturated PBS solution containing the complex
with an absorbance of 0.1 at the irradiation wave-
length, N,N-dimethyl-4-nitrosoaniline (RNO, 20 ?M) and
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histidine (10 mM). The samples were irradiated on 96
well plates with an Atlas Photonics LUMOS BIO
irradiator for different times. The absorbance of the
samples was measured during these time intervals
with a SpectraMax M2 Microplate Reader (Molecular
Devices). The difference in absorbance (A0A) at
420 nm for the MeCN solution or at 440 nm a PBS
buffer solution was calculated and plotted against the
irradiation times. From the plot the slope of the linear
regression was calculated as well as the absorbance
correction factor determined. The singlet oxygen
quantum yields were calculated using the same
formulas as used for the direct evaluation.
Cell Culture
HeLa cell line was cultured in DMEM (Gibco, Life
Technologies, USA) supplemented with 10% of fetal
calf serum (Gibco). RPE-1 cells were cultured in DMEM/
F-12 (Gibco) supplemented with 10% of fetal calf
serum. Cell lines were complemented with 100 U/ml
penicillin-streptomycin mixture (Gibco), and main-
tained in humidified atmosphere at 37 °C and 5% of
CO2.
Cytotoxicity Studies
Dark and light cytotoxicity of the Ru(II) complexes and
Ru(II) conjugates was assessed by fluorometric cell
viability assay using resazurin (ACROS Organics). For
light and dark cytotoxicity, HeLa and RPE-1 cells were
seeded in triplicates in 96 well plates at a density of
4000 cells per well in 100 ?l, 24 h prior to treatment.
Cells were then treated with increasing concentration
of compounds for 48 h. After that time, medium was
replaced by fresh complete medium. For light cytotox-
icity experiments HeLa and RPE-1 cells were exposed
to 480 nm light for 10 min in a 96-well plate using a
LUMOS-BIO photoreactor (Atlas Photonics). Each well
was individually illuminated with a 5 lm LED at
constant current (light dose 3.21 Jcm2). After 44 h in
the incubator medium was replaced by fresh complete
medium containing resazurin (0.2 mgml1 final con-
centration). After 4 h incubation at 37 °C, fluorescence
signal of resorufin product was read by SpectraMax M5
microplate reader (ex: 540 nm; em: 590 nm). IC50
values were calculated using GraphPad Prism software.
Localization Studies
Cellular localization of the Ru(II) compounds was
assessed by fluorescent microscopy. HeLa cells were
grown on the 12 mm Menzel–Gläser coverslips in 2 ml of
complete medium at a density of 1.3×105 cellsperml.
Cells were then treated with the compounds (IC50
concentration in the dark) for 2h, with NucBlue (two
drops per 1 ml of media) for the last 25 min and with
100 nm Mitotracker Green FM for the last 15 min. HeLa
cells were then fixed with paraformaldehyde solution in
PBS (4%) and mounted on glass slides using Prolong
Glass Antifade Mountant. Leica SP8 confocal microscope
was used to analyze the samples. Ru compounds were
excited at 488 nm and emission above 650 nm was
recorded. Images were recorded in Cellular and Molec-
ular Imaging Technical Platform, INSERM UMS 025–CNRS
UMS 3612, Faculty of Pharmacy of Paris, Paris Descartes
University, Paris, France.
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